Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carrie Steichen

Interventional Pain Medicine Pensacola, FL Doctor of Osteopathy

NPI 1710004544 CMS profile 349759

4624 N Davis Hwy, Pensacola, FL 32503

Open in the dashboard

General payments

$6,892

121 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carrie Steichen of Pensacola, FL is reported in the CMS Open Payments database as having received $6,892 across 121 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $679 22
2024 General $964 17
2023 General $823 13
2022 General $1,013 20
2021 General $697 18
2020 General $1,710 12
2019 General $1,006 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Steichen
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Carrie Steichen were reported at $679. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Carrie Steichen Interventional Pain Medicine median Middle half National median
2019 $1,006 $684 $216–$2,079 $163
2020 $1,710 $382 $122–$1,109 $114
2021 $697 $552 $167–$1,554 $132
2022 $1,013 $605 $187–$1,924 $149
2023 $823 $671 $195–$1,915 $160
2024 $964 $684 $206–$1,837 $164
2025 $679 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,887 42 payments
  2. Medtronic, Inc. $691 12 payments
  3. Abbott Laboratories $571 6 payments
  4. AbbVie, Inc. $231 12 payments
  5. Nevro Corp. $214 4 payments
  6. Medtronic USA, Inc. $197 5 payments
  7. MML US, Inc. $173 3 payments
  8. Relievant Medsystems, Inc. $144 1 payment
  9. Allergan Inc. $94 5 payments
  10. Lilly USA, LLC $81 2 payments
  11. Other $610 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,457 117 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,400 2 payments
  3. Education $35 2 payments
Products named General payments · program years 2019–2025
  1. GENERAL - PAIN MANAGEMENT $1,400 2 payments
  2. WaveWriter Alpha Prime 16 $933 18 payments
  3. Proclaim Family of SCS IPGs $431 4 payments
  4. WAVEWRITER ALPHA $369 4 payments
  5. INTELLIS ADAPTIVESTIM $353 5 payments
  6. Superion Indirect Decompression System $266 2 payments
  7. ReActiv8 $173 3 payments
  8. Senza Spinal Cord Stimulation System $171 2 payments
  9. INTELLIS $170 3 payments
  10. BOTOX $154 8 payments
  11. Other $2,179 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

3,686

Median for Pain Management: 951

Drug cost

$141,676

Median for Pain Management: $26,034

Branded share of claims

67.6%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,362 $35,082
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 867 $31,783
Botox Onabotulinumtoxina Brand 17 $18,795
Belbuca Buprenorphine Hcl Brand 22 $14,368
Buprenorphine Generic 71 $14,161
Pregabalin Generic 288 $6,822
Tramadol Hcl Er Tramadol Hcl Brand 72 $4,107
Morphine Sulfate Er Morphine Sulfate Brand 150 $2,989
Gabapentin Generic 178 $2,795
Tramadol Hcl Generic 218 $2,096

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$375,435

Of which drugs: $5,379

Medicare patients

935

Average age 73

Services billed

9,732

558 women, 377 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Chronic kidney disease 33%
Depression 33%
Ischemic heart disease 30%
Osteoporosis 25%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 11 84 $4,703
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 226 3,913 $336
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 140 766 $216
Injection, ketorolac tromethamine, per 15 mg J1885 Office 53 247 $124

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $9
$9 — —
BOTOX
  • AbbVie, Inc. $9
$9 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

121 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record